Oligodendrocyte Fate after Spinal Cord Injury

被引:0
|
作者
Akshata Almad
F. Rezan Sahinkaya
Dana M. McTigue
机构
[1] Ohio State University,Neuroscience Graduate Studies Program
[2] Ohio State University,Center for Brain and Spinal Cord Repair
[3] Ohio State University,Department of Neuroscience
来源
Neurotherapeutics | 2011年 / 8卷
关键词
Myelin; polydendrocytes; excitotoxicity; inflammation; transplant; macrophage;
D O I
暂无
中图分类号
学科分类号
摘要
Oligodendrocytes (OLs) are particularly susceptible to the toxicity of the acute lesion environment after spinal cord injury (SCI). They undergo both necrosis and apoptosis acutely, with apoptosis continuing at chronic time points. Loss of OLs causes demyelination and impairs axon function and survival. In parallel, a rapid and protracted OL progenitor cell proliferative response occurs, especially at the lesion borders. Proliferating and migrating OL progenitor cells differentiate into myelinating OLs, which remyelinate demyelinated axons starting at 2 weeks post-injury. The progression of OL lineage cells into mature OLs in the adult after injury recapitulates development to some degree, owing to the plethora of factors within the injury milieu. Although robust, this endogenous oligogenic response is insufficient against OL loss and demyelination. First, in this review we analyze the major spatial–temporal mechanisms of OL loss, replacement, and myelination, with the purpose of highlighting potential areas of intervention after SCI. We then discuss studies on OL protection and replacement. Growth factors have been used both to boost the endogenous progenitor response, and in conjunction with progenitor transplantation to facilitate survival and OL fate. Considerable progress has been made with embryonic stem cell-derived cells and adult neural progenitor cells. For therapies targeting oligogenesis to be successful, endogenous responses and the effects of the acute and chronic lesion environment on OL lineage cells must be understood in detail, and in relation, the optimal therapeutic window for such strategies must also be determined.
引用
收藏
页码:262 / 273
页数:11
相关论文
共 50 条
  • [1] Oligodendrocyte Fate after Spinal Cord Injury
    Almad, Akshata
    Sahinkaya, F. Rezan
    McTigue, Dana M.
    NEUROTHERAPEUTICS, 2011, 8 (02) : 262 - 273
  • [2] The fate and function of oligodendrocyte progenitor cells after traumatic spinal cord injury
    Duncan, Greg J.
    Manesh, Sohrab B.
    Hilton, Brett J.
    Assinck, Peggy
    Plemel, Jason R.
    Tetzlaff, Wolfram
    GLIA, 2020, 68 (02) : 227 - 245
  • [3] Fate mapping of oligodendrocyte precursor cells (OPCs) after spinal cord injury and role of oligodendrocyte remyelination in functional recovery
    Tetzlaff, W.
    GLIA, 2017, 65 : E49 - E50
  • [4] Increase of oligodendrocyte progenitor cells after spinal cord injury
    Ishii, K
    Toda, M
    Nakai, Y
    Asou, H
    Watanabe, M
    Nakamura, M
    Yato, Y
    Fujimura, Y
    Kawakami, Y
    Toyama, Y
    Uyemura, K
    JOURNAL OF NEUROSCIENCE RESEARCH, 2001, 65 (06) : 500 - 507
  • [5] MOLECULAR REGULATION OF OLIGODENDROCYTE DIFFERENTIATION AFTER SPINAL CORD INJURY
    Whittemore, S. R.
    JOURNAL OF NEUROCHEMISTRY, 2009, 108 : 21 - 22
  • [6] Oligodendrocyte apoptosis is selectively attenuated by methylprednisolone after spinal cord injury
    Yan, P.
    Lee, J.
    Chen, S.
    Liu, Q.
    Hsu, C.
    Xu, J.
    JOURNAL OF NEUROTRAUMA, 2006, 23 (06) : 995 - 995
  • [7] Control of oligodendrocyte plasticity by histone demethylases after spinal cord injury
    Duman, O. M.
    Jacob, C.
    GLIA, 2015, 63 : E415 - E415
  • [8] THE RESPONSES OF MOTOR NEURON AND OLIGODENDROCYTE PROGENITORS AFTER SPINAL CORD INJURY
    Zhou, Y.
    Arena, K.
    Appel, B.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2024, 72 (01) : 518 - 519
  • [9] Leukemia inhibitory factor promotes oligodendrocyte survival after spinal cord injury
    Kerr, BJ
    Patterson, PH
    GLIA, 2005, 51 (01) : 73 - 79
  • [10] Amiloride Promotes Oligodendrocyte Survival and Remyelination after Spinal Cord Injury in Rats
    Imai, Takeshi
    Katoh, Hiroyuki
    Suyama, Kaori
    Kuroiwa, Masahiro
    Yanagisawa, Sho
    Watanabe, Masahiko
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (03):